Transdiagnostic Proteomic Changes in Neurodegeneration

Transdiagnostic Proteomic Changes in Neurodegeneration

Introduction

Transdiagnostic proteomics examines shared protein alterations across multiple neurodegenerative diseases, revealing common molecular pathways that transcend traditional diagnostic boundaries. Large-scale proteomic studies have identified conserved signatures in [Alzheimer's disease](/diseases/alzheimers-disease) (AD), [Parkinson's disease](/diseases/parkinsons-disease) (PD), and [frontotemporal dementia](/diseases/behavioral-variant-ftd) (FTD), suggesting common underlying mechanisms of neuronal vulnerability and glial dysfunction[@bai2023].

Shared Proteomic Signatures Across Neurodegenerative Diseases

Core Protein Alterations

Multiple studies have identified a core set of proteins consistently altered across neurodegenerative conditions:

```mermaid
flowchart TD
A["Shared Proteomic<br/>Signatures"] --> B["Immune/Inflammatory<br/>Proteins"]
A --> C["Synaptic Proteins"]
A --> D["Lysosomal/Autophagy<br/>Proteins"]
A --> E["Metabolic Enzymes"]

B --> B1["C3, C4, CFH<br/>Complement"]
B --> B2["TREM2, CD33<br/>Microglial"]
B --> B3["IL6, IL1beta<br/>Cytokines"]

C --> C1["SNAP25, SYN1<br/>Synaptic Vesicle"]
C --> C2["PSD95, GRIN1<br/>Postsynaptic"]

D --> D1["LAMP1/2, CTSB<br/>Lysosomal"]
D --> D2["ATG proteins<br/>Autophagy"]

E --> E1["GAPDH, Enolase<br/>Glycolysis"]
E --> E2["ATP5A, Complex I<br/>Mitochondrial"]

Transdiagnostic Proteomic Changes in Neurodegeneration

Introduction

Transdiagnostic proteomics examines shared protein alterations across multiple neurodegenerative diseases, revealing common molecular pathways that transcend traditional diagnostic boundaries. Large-scale proteomic studies have identified conserved signatures in [Alzheimer's disease](/diseases/alzheimers-disease) (AD), [Parkinson's disease](/diseases/parkinsons-disease) (PD), and [frontotemporal dementia](/diseases/behavioral-variant-ftd) (FTD), suggesting common underlying mechanisms of neuronal vulnerability and glial dysfunction[@bai2023].

Shared Proteomic Signatures Across Neurodegenerative Diseases

Core Protein Alterations

Multiple studies have identified a core set of proteins consistently altered across neurodegenerative conditions:

Disease-Specific vs. Shared Changes

While some protein changes are disease-specific, others represent a common "neurodegenerative proteomic signature"[@zhou2023]:

| Category | Shared Changes | Disease-Specific |
|----------|----------------|------------------|
| Immune | C3, C4, TREM2, complement factors | Disease-specific cytokine patterns |
| Synaptic | SNAP25, synaptophysin reduction | PSD95 alterations in AD |
| Lysosomal | LAMP1/2, cathepsins | GBA variants in PD |
| Metabolic | Glycolysis enzymes | Complex I in PD |

APOE ε4 Carrier Proteomic Signatures

The [APOE](/genes/apoe) ε4 allele represents the strongest genetic risk factor for AD and influences neurodegeneration across diagnostic categories. Proteomic studies have identified distinct signatures in ε4 carriers[@zhou2023a]:

Brain Tissue Proteomics

Key findings in APOE ε4 carriers:

• Complement system activation: Elevated C1Q, C3, and C4b in brain tissue and cerebrospinal fluid[@shi2017]
• Lipid metabolism dysregulation: Altered APOE, APOA1, and APOH levels
• Synaptic protein reductions: Enhanced vulnerability of postsynaptic density proteins
• TREM2-related microglial changes: Altered microglial activation patterns

Cerebrospinal Fluid Proteomics

CSF studies in APOE ε4 carriers reveal[@cruchaga2013]:

Transdiagnostic Effects

APOE ε4 effects extend beyond AD to[@tsuang2013]:

• Parkinson's disease: Earlier onset, more rapid progression
• FTD: Modified clinical presentation in some subtypes
• Lewy body dementia: Enhanced cortical Lewy body pathology

Immune-Related Proteomic Changes

Complement System Activation

The complement system represents a central hub of transdiagnostic proteomic changes[@morgan2021]:

Upregulated in multiple diseases:

• C1Q (classical pathway initiator)
• C3 (central complement component)
• C4 (alternative and classical pathways)
• CFH (complement factor H)

• Synaptic pruning dysregulation
• Microglial activation modulation
• Neuroinflammation amplification

Microglial-Associated Proteins

Proteomic studies consistently identify microglial alterations[@yeh2022]:

| Protein | AD | PD | FTD | Function |
|---------|----|----|-----|----------|
| TREM2 | ↑ | ↑ | ↑ | Phagocytic receptor |
| CD33 | ↑ | Variable | ↑ | Siglec receptor |
| CX3CR1 | ↓ | ↓ | ↓ | Fractalkine receptor |
| IBA1/AIF1 | ↑ | ↑ | ↑ | Microglial marker |

Cytokine and Chemokine Alterations

Transdiagnostic cytokine signatures include[@chen2021]:

• Pro-inflammatory: IL-1β, IL-6, TNF-α
• Chemokines: CCL2, CCL3, CXCL8
• Anti-inflammatory: IL-10, TGF-β (often dysregulated)

Cross-Disease Proteomic Networks

Network analysis reveals conserved molecular modules across neurodegenerative conditions[@seyfried2017]:

Module 1: Synaptic Dysfunction

Common to AD, PD, FTD, and ALS:

• SNAP25, SYN1, SYN2 reduction
• PSD95 (DLG4) alterations
• Neurogranin (RC3) changes

Module 2: Protein Quality Control

Shared autophagy/lysosome changes:

• LAMP1/2 alterations
• Cathepsin B/D dysregulation
• Ubiquitin-proteasome system changes

Module 3: Metabolic Dysfunction

Energy metabolism commonalities:

• Glycolysis enzyme alterations (GAPDH, enolase)
• Mitochondrial Complex I changes (especially PD)
• ATP synthase modifications

Module 4: Cytoskeletal Abnormalities

• Neurofilament light chain (NfL) elevation
• Alpha-synuclein modifications
• Tau protein alterations

Biomarker Implications

Transdiagnostic proteomic signatures have diagnostic and prognostic utility[@blennow2020]:

Current Biomarkers

| Biomarker | Cross-Disease Relevance |
|-----------|------------------------|
| Neurofilament light chain (NfL) | AD, PD, FTD, ALS |
| YKL-40 | AD, PD, FTD |
| TREM2 | AD, FTD |
| GFAP | AD, PD |

Emerging Targets

• phospho-tau species: Disease-specific patterns
• Alpha-synuclein: PD/DLB specific
• TDP-43: ALS/FTD specific

Therapeutic Implications

Understanding transdiagnostic proteomic changes identifies shared therapeutic targets[@zhang2024]:

Priority Targets

Precision Medicine Considerations

While shared mechanisms exist, disease-specific approaches remain important:

• APOE ε4 status modifies treatment responses
• Genetic subtypes (GBA, LRRK2, C9orf72) have distinct signatures
• Age at onset influences proteomic patterns

See Also

• [Alzheimer's disease](/diseases/alzheimers-disease)
• [Parkinson's disease](/diseases/parkinsons-disease)
• [frontotemporal dementia](/diseases/behavioral-variant-ftd)
• [APOE](/genes/apoe)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References